Cargando…

Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital

INTRODUCTION: Medullary thyroid carcinoma may occur in a sporadic (s-medullary thyroid carcinoma, 75%) or in a multiple endocrine neoplasia type 2 form (MEN2, 25%). These clinical forms differ in many ways, as s-medullary thyroid carcinoma cases are RET-negative in the germline and are typically dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Correia-Deur, Joya Emilie M., Toledo, Rodrigo A., Imazawa, Alice T., Lourenço, Delmar M., Ezabella, Marilza C. L., Tavares, Marcos R., Toledo, Sergio P. A.
Formato: Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694239/
https://www.ncbi.nlm.nih.gov/pubmed/19488601
http://dx.doi.org/10.1590/S1807-59322009000500002
_version_ 1782168057825722368
author Correia-Deur, Joya Emilie M.
Toledo, Rodrigo A.
Imazawa, Alice T.
Lourenço, Delmar M.
Ezabella, Marilza C. L.
Tavares, Marcos R.
Toledo, Sergio P. A.
author_facet Correia-Deur, Joya Emilie M.
Toledo, Rodrigo A.
Imazawa, Alice T.
Lourenço, Delmar M.
Ezabella, Marilza C. L.
Tavares, Marcos R.
Toledo, Sergio P. A.
author_sort Correia-Deur, Joya Emilie M.
collection PubMed
description INTRODUCTION: Medullary thyroid carcinoma may occur in a sporadic (s-medullary thyroid carcinoma, 75%) or in a multiple endocrine neoplasia type 2 form (MEN2, 25%). These clinical forms differ in many ways, as s-medullary thyroid carcinoma cases are RET-negative in the germline and are typically diagnosed later than medullary thyroid carcinoma in MEN2 patients. In this study, a set of cases with s-medullary thyroid carcinoma are documented and explored. PURPOSE: To document the phenotypes observed in s-medullary thyroid carcinoma cases from a university group and to attempt to improve earlier diagnosis of s-medullary thyroid carcinoma. Some procedures for diagnostics are also recommended. METHOD: Patients (n=26) with apparent s-medullary thyroid carcinoma were studied. Their clinical data were reviewed and peripheral blood was collected and screened for RET germline mutations. RESULTS: The average age at diagnosis was 43.9 years (± 10.82 SD) and did not differ between males and females. Calcitonin levels were increased in all cases. Three patients presented values that were 100-fold greater than the normal upper limit. Most (61.54%) had values that were 20-fold below this limit. Carcinoembryonic antigen levels were high in 70.6% of cases. There was no significant association between age at diagnosis, basal calcitonin levels or time of disease onset with thyroid tumor size (0.6–15 cm). Routine thyroid cytology yielded disappointing diagnostic accuracy (46.7%) in this set of cases. After total thyroidectomy associated with extensive cervical lymph node resection, calcitonin values remained lower than 5 pg/mL for at least 12 months in eight of the cases (30.8%). Immunocyto- and histochemistry for calcitonin were positive in all analyzed cases. None of the 26 cases presented germline mutations in the classical hotspots of the RET proto-oncogene. CONCLUSION: Our cases were identified late. The basal calcitonin measurements and immunostaining for calcitonin were highly useful for diagnosing s-medullary thyroid carcinoma. The rate of complete patient recovery was low, and none of the parameters analyzed were useful predictors of the thyroid tumor size. Our findings support previous recommendations for routine serum calcitonin evaluation and immunostaining analysis involving single thyroid nodules.
format Text
id pubmed-2694239
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-26942392009-06-16 Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital Correia-Deur, Joya Emilie M. Toledo, Rodrigo A. Imazawa, Alice T. Lourenço, Delmar M. Ezabella, Marilza C. L. Tavares, Marcos R. Toledo, Sergio P. A. Clinics (Sao Paulo) Clinical Sciences INTRODUCTION: Medullary thyroid carcinoma may occur in a sporadic (s-medullary thyroid carcinoma, 75%) or in a multiple endocrine neoplasia type 2 form (MEN2, 25%). These clinical forms differ in many ways, as s-medullary thyroid carcinoma cases are RET-negative in the germline and are typically diagnosed later than medullary thyroid carcinoma in MEN2 patients. In this study, a set of cases with s-medullary thyroid carcinoma are documented and explored. PURPOSE: To document the phenotypes observed in s-medullary thyroid carcinoma cases from a university group and to attempt to improve earlier diagnosis of s-medullary thyroid carcinoma. Some procedures for diagnostics are also recommended. METHOD: Patients (n=26) with apparent s-medullary thyroid carcinoma were studied. Their clinical data were reviewed and peripheral blood was collected and screened for RET germline mutations. RESULTS: The average age at diagnosis was 43.9 years (± 10.82 SD) and did not differ between males and females. Calcitonin levels were increased in all cases. Three patients presented values that were 100-fold greater than the normal upper limit. Most (61.54%) had values that were 20-fold below this limit. Carcinoembryonic antigen levels were high in 70.6% of cases. There was no significant association between age at diagnosis, basal calcitonin levels or time of disease onset with thyroid tumor size (0.6–15 cm). Routine thyroid cytology yielded disappointing diagnostic accuracy (46.7%) in this set of cases. After total thyroidectomy associated with extensive cervical lymph node resection, calcitonin values remained lower than 5 pg/mL for at least 12 months in eight of the cases (30.8%). Immunocyto- and histochemistry for calcitonin were positive in all analyzed cases. None of the 26 cases presented germline mutations in the classical hotspots of the RET proto-oncogene. CONCLUSION: Our cases were identified late. The basal calcitonin measurements and immunostaining for calcitonin were highly useful for diagnosing s-medullary thyroid carcinoma. The rate of complete patient recovery was low, and none of the parameters analyzed were useful predictors of the thyroid tumor size. Our findings support previous recommendations for routine serum calcitonin evaluation and immunostaining analysis involving single thyroid nodules. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2009-05 /pmc/articles/PMC2694239/ /pubmed/19488601 http://dx.doi.org/10.1590/S1807-59322009000500002 Text en Copyright © 2009 Hospital das Clínicas da FMUSP
spellingShingle Clinical Sciences
Correia-Deur, Joya Emilie M.
Toledo, Rodrigo A.
Imazawa, Alice T.
Lourenço, Delmar M.
Ezabella, Marilza C. L.
Tavares, Marcos R.
Toledo, Sergio P. A.
Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital
title Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital
title_full Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital
title_fullStr Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital
title_full_unstemmed Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital
title_short Sporadic Medullary Thyroid Carcinoma: Clinical Data From A University Hospital
title_sort sporadic medullary thyroid carcinoma: clinical data from a university hospital
topic Clinical Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694239/
https://www.ncbi.nlm.nih.gov/pubmed/19488601
http://dx.doi.org/10.1590/S1807-59322009000500002
work_keys_str_mv AT correiadeurjoyaemiliem sporadicmedullarythyroidcarcinomaclinicaldatafromauniversityhospital
AT toledorodrigoa sporadicmedullarythyroidcarcinomaclinicaldatafromauniversityhospital
AT imazawaalicet sporadicmedullarythyroidcarcinomaclinicaldatafromauniversityhospital
AT lourencodelmarm sporadicmedullarythyroidcarcinomaclinicaldatafromauniversityhospital
AT ezabellamarilzacl sporadicmedullarythyroidcarcinomaclinicaldatafromauniversityhospital
AT tavaresmarcosr sporadicmedullarythyroidcarcinomaclinicaldatafromauniversityhospital
AT toledosergiopa sporadicmedullarythyroidcarcinomaclinicaldatafromauniversityhospital